Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.

Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Kitange GJ, Shen Y, Feng Y, Protter AA, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2017 Dec;16(12):2735-2746. doi: 10.1158/1535-7163.MCT-17-0365. Epub 2017 Sep 25.

PMID:
28947502
2.

Radioresistance of Brain Tumors.

Kelley K, Knisely J, Symons M, Ruggieri R.

Cancers (Basel). 2016 Mar 30;8(4). pii: E42. doi: 10.3390/cancers8040042. Review.

3.

Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model.

Lemasson B, Wang H, Galbán S, Li Y, Zhu Y, Heist KA, Tsein C, Chenevert TL, Rehemtulla A, Galbán CJ, Holland EC, Ross BD.

Neoplasia. 2016 Feb;18(2):82-9. doi: 10.1016/j.neo.2015.11.014.

4.

Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.

Gupta SK, Kizilbash SH, Carlson BL, Mladek AC, Boakye-Agyeman F, Bakken KK, Pokorny JL, Schroeder MA, Decker PA, Cen L, Eckel-Passow JE, Sarkar G, Ballman KV, Reid JM, Jenkins RB, Verhaak RG, Sulman EP, Kitange GJ, Sarkaria JN.

J Natl Cancer Inst. 2015 Nov 27;108(5). pii: djv369. doi: 10.1093/jnci/djv369. Print 2016 May.

5.

What next for newly diagnosed glioblastoma?

Domingo-Musibay E, Galanis E.

Future Oncol. 2015;11(24):3273-83. doi: 10.2217/fon.15.258. Epub 2015 Nov 12. Review.

6.

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.

Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Schroeder MA, Sludden J, Boddy AV, Agar NY, Curtin NJ, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2015 Dec;14(12):2735-43. doi: 10.1158/1535-7163.MCT-15-0553. Epub 2015 Oct 5.

7.

The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.

Pokorny JL, Calligaris D, Gupta SK, Iyekegbe DO Jr, Mueller D, Bakken KK, Carlson BL, Schroeder MA, Evans DL, Lou Z, Decker PA, Eckel-Passow JE, Pucci V, Ma B, Shumway SD, Elmquist WF, Agar NY, Sarkaria JN.

Clin Cancer Res. 2015 Apr 15;21(8):1916-24. doi: 10.1158/1078-0432.CCR-14-2588. Epub 2015 Jan 21.

8.

Contemporary murine models in preclinical astrocytoma drug development.

McNeill RS, Vitucci M, Wu J, Miller CR.

Neuro Oncol. 2015 Jan;17(1):12-28. doi: 10.1093/neuonc/nou288. Epub 2014 Sep 21. Review.

9.

A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.

Kim SS, Rait A, Kim E, Pirollo KF, Chang EH.

Nanomedicine. 2015 Feb;11(2):301-11. doi: 10.1016/j.nano.2014.09.005. Epub 2014 Sep 18.

10.

Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.

Gupta SK, Mladek AC, Carlson BL, Boakye-Agyeman F, Bakken KK, Kizilbash SH, Schroeder MA, Reid J, Sarkaria JN.

Clin Cancer Res. 2014 Jul 15;20(14):3730-41. doi: 10.1158/1078-0432.CCR-13-3446. Epub 2014 May 16.

11.

Improving the efficacy of chemoradiation with targeted agents.

Morgan MA, Parsels LA, Maybaum J, Lawrence TS.

Cancer Discov. 2014 Mar;4(3):280-91. doi: 10.1158/2159-8290.CD-13-0337. Epub 2014 Feb 18. Review.

12.

Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator.

Gupte M, Tuck AN, Sharma VP, Williams KJ.

PLoS One. 2013 Sep 3;8(9):e74071. doi: 10.1371/journal.pone.0074071. eCollection 2013.

13.

Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.

Curtin NJ.

Br J Pharmacol. 2013 Aug;169(8):1745-65. doi: 10.1111/bph.12244. Review.

14.

Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.

Barazzuol L, Jena R, Burnet NG, Meira LB, Jeynes JC, Kirkby KJ, Kirkby NF.

Radiat Oncol. 2013 Mar 19;8:65. doi: 10.1186/1748-717X-8-65.

15.

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.

Cen L, Carlson BL, Pokorny JL, Mladek AC, Grogan PT, Schroeder MA, Decker PA, Anderson SK, Giannini C, Wu W, Ballman KV, Kitange GJ, Sarkaria JN.

Neuro Oncol. 2013 Jun;15(6):735-46. doi: 10.1093/neuonc/not010. Epub 2013 Mar 10.

16.

Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Curtin NJ, Szabo C.

Mol Aspects Med. 2013 Dec;34(6):1217-56. doi: 10.1016/j.mam.2013.01.006. Epub 2013 Jan 29. Review.

17.

Incorporation of prognostic and predictive factors into glioma clinical trials.

Johnson DR, Galanis E.

Curr Oncol Rep. 2013 Feb;15(1):56-63. doi: 10.1007/s11912-012-0279-z. Review.

18.

p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.

Cen L, Carlson BL, Schroeder MA, Ostrem JL, Kitange GJ, Mladek AC, Fink SR, Decker PA, Wu W, Kim JS, Waldman T, Jenkins RB, Sarkaria JN.

Neuro Oncol. 2012 Jul;14(7):870-81. doi: 10.1093/neuonc/nos114. Epub 2012 Jun 18.

19.

Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.

Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Cen L, Decker PA, Wu W, Lomberk GA, Gupta SK, Urrutia RA, Sarkaria JN.

Clin Cancer Res. 2012 Aug 1;18(15):4070-9. doi: 10.1158/1078-0432.CCR-12-0560. Epub 2012 Jun 6.

20.

The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.

Javle M, Curtin NJ.

Ther Adv Med Oncol. 2011 Nov;3(6):257-67. doi: 10.1177/1758834011417039.

Supplemental Content

Support Center